Ketamine could soon be approved to treat depression
Psychiatrists looking for a new treatment to give patients with major depression and suicidal tendencies may soon be able to administer ketamine inside of their offices.
If ketamine is approved by the Federal Drug Administration as a breakthrough therapy, it will be the first new treatment for a major depressive disorder in about 50 years, CNN reports. On Tuesday, Janssen Pharmaceutical announced it is working on two clinical trials with ketamine — one for treatment-resistant depression and one for depression with suicidal thoughts, and will present the data to the FDA in 2018. Ketamine is also known as the street drug Special K, which gives users the feeling of being out of their body. It was used in the 1960s as an analgesic and sedative and is still on the World Health Organization's Essential Medicine List, but because of its hallucinogenic side effects, it's mostly used today as a veterinary anesthetic.
Depression causes damage to nerves and their transmission pathways, and research leads scientists to believe ketamine remodels those nerves, triggering neuroplastic processes that make new connections among brain cells, Dr. Dan Iosifescu of the Icahn School of Medicine at Mount Sinai in New York City told CNN. "What's unique about ketamine is, this happens in hours or days, while with other depression medications, this happens in weeks to months," he said. Doctors have some concern that using ketamine for depression could reverse a person's tolerance to opioids or lead to substance abuse, and Janssen said its formulation would only be administered by a doctor in their office.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
There’s a new serif in town: Trump’s font overhaulIn the Spotlight As the State Department shifts from Calibri to Times New Roman, is this just a ‘typographic dispute’, or the ‘latest battleground’ of a culture war
-
Do you have to pay taxes on student loan forgiveness?The Explainer As of 2026, some loan borrowers may face a sizable tax bill
-
Planning a move? Here are the steps to take next.the explainer Stay organized and on budget
-
Why Greenland’s natural resources are nearly impossible to mineThe Explainer The country’s natural landscape makes the task extremely difficult
-
Iran cuts internet as protests escalateSpeed Reada Government buildings across the country have been set on fire
-
US nabs ‘shadow’ tanker claimed by RussiaSpeed Read The ship was one of two vessels seized by the US military
-
Maduro pleads not guilty in first US court hearingSpeed Read Deposed Venezuelan leader Nicolás Maduro and his wife Cilia Flores pleaded not guilty to cocaine trafficking and narco-terrorism conspiracy
-
Iran’s government rocked by protestsSpeed Read The death toll from protests sparked by the collapse of Iran’s currency has reached at least 19
-
Israel approves new West Bank settlementsSpeed Read The ‘Israeli onslaught has all but vanquished a free Palestinian existence in the West Bank’
-
US offers Ukraine NATO-like security pact, with caveatsSpeed Read The Trump administration has offered Ukraine security guarantees similar to those it would receive from NATO
-
Hong Kong court convicts democracy advocate LaiSpeed Read Former Hong Kong media mogul Jimmy Lai was convicted in a landmark national security trial
